Board meeting outcome for intimation for submission of Financial Results for the quarter and the year ended as on 31st March,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.6 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Vasundhara Rasayans approved its audited financial results for the quarter and full year ended 31 March 2025, along with a clean (unmodified) audit opinion from statutory auditors Mamta Jain & Associates. For FY25, net sales dipped to Rs 3,399.01 lakhs from Rs 3,701.84 lakhs (down ~8% YoY), while profit after tax fell sharply to Rs 424.63 lakhs from Rs 585.93 lakhs (down ~27%). Q4FY25 was especially weak — net sales of Rs 775.60 lakhs were down ~31% YoY and Q4 PAT of Rs 44.63 lakhs was down ~79% YoY, dragging EPS down to Rs 13.39 from Rs 18.44. The balance sheet, however, stayed healthy with total equity rising to Rs 3,555.85 lakhs, though borrowings more than doubled to Rs 420.61 lakhs and operating cash flow swung to a negative Rs 583.46 lakhs (vs positive Rs 602.99 lakhs last year).
Negative for the stock — declining revenue, sharply lower profits and the swing to negative operating cash flow suggest business weakness that may pressure the share price despite the unchanged, unmodified auditor opinion and a still-solid equity base.